- World Pharma News Home » Product » Follicular lymphoma: EU approval for Zevalin® as First-Line Consolidation Treatment
(a free service delivered by FeedBurner)
The European Commission has extended the marketing authorization for Zevalin® ([90Y]-ibritumomab tiuxetan) in Europe. Zevalin can now be used in the course of a first-line therapy after remission induction in previously untreated patients with follicular lymphoma. The aim of such a consolidation therapy is the improvement of the effect of an initial induction therapy. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. Zevalin was initially approved in Europe in 2004. It combines the tumor-targeting ability of an anti-CD20 monoclonal antibody and the tumor-destroying power of localized yttrium-90 radiation. Follicular lymphoma is one of the most common types of Non-Hodgkin's Lymphoma, a tumor of the lymphatic system.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments